Uncategorized

Lilly bets up to $1B+ with AlzeCure in search for next Alzheimer’s act

Published

on

The star of the licensing agreement, a small-molecule gamma-secretase modulator, will help buff Eli Lilly’s position in Alzheimer’s disease, currently headlined by its anti-amyloid antibody Kisunla.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version